Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study

Andrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, Weily Soong, Sebastien Barbarot, Ileana Ionita, Fan Zhang, Hernan Valdez, Claire Clibborn, Natalie Yin, Andrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, Weily Soong, Sebastien Barbarot, Ileana Ionita, Fan Zhang, Hernan Valdez, Claire Clibborn, Natalie Yin

Abstract

Introduction: Atopic dermatitis (AD) can affect multiple body regions and is especially burdensome when involving exposed skin areas. Rapid, effective treatment of AD across body regions remains an unmet need, particularly for difficult-to-treat areas such as the head and neck area. We investigated the temporal and regional patterns of clinical improvement in AD with the use of abrocitinib, an orally available Janus kinase 1 selective inhibitor under development for the treatment of moderate-to-severe AD.

Methods: We performed a post hoc analysis of data from JADE COMPARE, a phase 3, multicenter, randomized, double-blind, double-dummy trial that evaluated the efficacy and safety of abrocitinib 200 mg once daily, abrocitinib 100 mg once daily, dupilumab 300 mg subcutaneous injection every 2 weeks, and placebo in adult patients with moderate-to-severe AD who were concomitantly receiving medicated topical therapy. Assessments included the Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD) index.

Results: With abrocitinib 200 mg, time to ≥ 75% improvement in EASI (EASI-75) occurred at a median of 29 days across body regions, including the head and neck region. With abrocitinib 100 mg, EASI-75 response was achieved at a median of 30-32 days for the trunk and lower limbs, and at 56-57 days for the head and neck region and upper limbs. With dupilumab, EASI-75 response was achieved at a median of 43 days for the trunk and 57 days for other regions. EASI body region scores significantly improved with abrocitinib 200 mg and 100 mg versus placebo at week 2 (p < 0.0001 for all comparisons). Improvements with abrocitinib were maintained up to week 16.

Conclusions: Rapid and persistent improvement in AD across all body regions was observed with abrocitinib treatment. Abrocitinib may be useful in patients with AD that affects difficult-to-treat anatomical areas or who require a rapid response.

Trial registration: Clinicaltrials.gov identifier: NCT03720470.

Keywords: Abrocitinib; Atopic dermatitis; EASI; Regional improvement; SCORAD; Temporal improvement.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve of time to first achieve ≥ 75% improvement from baseline in EASI body region score. EASI Eczema Area and Severity Index, EASI-75 ≥ 75% improvement in EASI from baseline, Q2W every 2 weeks, QD once daily
Fig. 2
Fig. 2
Least squares mean percentage change from baseline in EASI body region score at weeks 2, 4, 8, 12, and 16. CI Confidence interval
Fig. 3
Fig. 3
Least squares mean percentage change from baseline in EASI body region subscores for area of involvement (a) and severity (erythema, induration/papulation, excoriation, and lichenification) (b) at week 2

References

    1. Silverberg JI, Margolis DJ, Boguniewicz M, et al. Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019;33(7):1341–1348. doi: 10.1111/jdv.15574.
    1. Ring J, Zink A, Arents BWM, et al. Atopic eczema: burden of disease and individual suffering—results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33(7):1331–1340. doi: 10.1111/jdv.15634.
    1. Holm EA, Esmann S, Jemec GB. Does visible atopic dermatitis affect quality of life more in women than in men? Gend Med. 2004;1(2):125–130. doi: 10.1016/S1550-8579(04)80017-2.
    1. Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760–1767. doi: 10.1111/jdv.13689.
    1. Chernyshov PV. Stigmatization and self-perception in children with atopic dermatitis. Clin Cosmet Investig Dermatol. 2016;9:159–166. doi: 10.2147/CCID.S91263.
    1. Misery L, Seneschal J, Reguiai Z, et al. The impact of atopic dermatitis on sexual health. J Eur Acad Dermatol Venereol. 2019;33(2):428–432. doi: 10.1111/jdv.15223.
    1. Gupta MA, Pur DR, Vujcic B, Gupta AK. Suicidal behaviors in the dermatology patient. Clin Dermatol. 2017;35(3):302–311. doi: 10.1016/j.clindermatol.2017.01.006.
    1. Lio PA, Wollenberg A, Thyssen JP, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943–948. doi: 10.36849/JDD.2020.5422.
    1. Silverberg JI, Gelfand JM, Margolis DJ, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract. 2019;7(8):2699–706 e7. doi: 10.1016/j.jaip.2019.05.055.
    1. Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279–286. doi: 10.1007/s00403-013-1402-1.
    1. Sibbald C, Drucker AM. Patient burden of atopic dermatitis. Dermatol Clin. 2017;35(3):303–316. doi: 10.1016/j.det.2017.02.004.
    1. von Kobyletzki LB, Thomas KS, Schmitt J, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol. 2017;97(1):86–90. doi: 10.2340/00015555-2480.
    1. Egeberg A, Thyssen JP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019;81(4):943–949. doi: 10.1016/j.jaad.2019.06.018.
    1. Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis. J Dermatol. 2018;45(2):150–157. doi: 10.1111/1346-8138.14116.
    1. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. doi: 10.1016/j.anai.2017.10.039.
    1. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups—variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27(4):340–357. doi: 10.1111/exd.13514.
    1. Maarouf M, Saberian C, Lio PA, Shi VY. Head-and-neck dermatitis: Diagnostic difficulties and management pearls. Pediatr Dermatol. 2018;35(6):748–753. doi: 10.1111/pde.13642.
    1. Jaros J, Hendricks AJ, Shi VY, Lio PA. A practical approach to recalcitrant face and neck dermatitis in atopic dermatitis. Dermatitis. 2020;31(3):169–177. doi: 10.1097/DER.0000000000000590.
    1. Jang DH, Heo SJ, Jung HJ, Park MY, Seo SJ, Ahn J. Retrospective study of dupilumab treatment for moderate to severe atopic dermatitis in Korea: efficacy and safety of dupilumab in real-world practice. J Clin Med. 2020;9(6):1982. doi: 10.3390/jcm9061982.
    1. Soria A, Du-Thanh A, Seneschal J, Jachiet M, Staumont-Sallé D, Barbarot S. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(11):1312–1315. doi: 10.1001/jamadermatol.2019.2613.
    1. Waldman RA, DeWane ME, Sloan B, Grant-Kels JM. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230–232. doi: 10.1016/j.jaad.2019.06.026.
    1. Zhu GA, Chen JK, Chiou A, Ko J, Honari G. Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol. 2019;155(7):850–852. doi: 10.1001/jamadermatol.2019.0109.
    1. Muzumdar S, Zubkov M, Waldman R, DeWane ME, Wu R, Grant-Kels JM. Characterizing dupilumab facial redness in children and adolescents: a single-institution retrospective chart review. J Am Acad Dermatol. 2020;83(5):1520–1521. doi: 10.1016/j.jaad.2020.06.1003.
    1. Vazquez ML, Kaila N, Strohbach JW, et al. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfo namide (PF-04965842): a selective JAK1 clinical candidate for the treatment of autoimmune diseases. J Med Chem. 2018;61(3):1130–1152. doi: 10.1021/acs.jmedchem.7b01598.
    1. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi: 10.1016/S0140-6736(20)30732-7.
    1. Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873. doi: 10.1001/jamadermatol.2020.1406.
    1. Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–1112. doi: 10.1056/NEJMoa2019380.
    1. Silverberg JI, Saeki H, Nosbaum A, et al. Efficacy of abrocitinib monotherapy by body location in patients with moderate-to-severe atopic dermatitis: pooled results from phase 2b/3 studies. In: 29th EADV congress; October 28-November 1, 2020. EADV Virtual2020.
    1. Okubo Y, Ho KA, Fifer S, Fujita H, Oki Y, Taguchi Y. Patient and physician preferences for atopic dermatitis injection treatments in Japan. J Dermatolog Treat. 2020;31(8):821–30.
    1. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590. doi: 10.1016/j.jid.2018.08.028.
    1. Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154(8):903–912. doi: 10.1001/jamadermatol.2018.1572.
    1. de Bruin-Weller M, Gadkari A, Auziere S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–1036. doi: 10.1111/jdv.16003.
    1. Silverberg JI, Gelfand JM, Margolis DJ, et al. Health utility scores of atopic dermatitis in US Adults. J Allergy Clin Immunol Pract. 2019;7(4):1246–52 e1. doi: 10.1016/j.jaip.2018.11.043.
    1. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–347. doi: 10.1016/j.anai.2018.07.006.
    1. Howell MD, Kuo FI, Smith PA. Targeting the janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. doi: 10.3389/fimmu.2019.02342.
    1. Yasuda T, Fukada T, Nishida K, et al. Hyperactivation of JAK1 tyrosine kinase induces stepwise, progressive pruritic dermatitis. J Clin Invest. 2016;126(6):2064–2076. doi: 10.1172/JCI82887.
    1. Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. Br J Dermatol. 2019;181(1):196–197. doi: 10.1111/bjd.17703.
    1. de Wijs LEM, Nguyen NT, Kunkeler ACM, Nijsten T, Damman J, Hijnen DJ. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series. Br J Dermatol. 2020;183(4):745–749. doi: 10.1111/bjd.18730.
    1. Seok SH, An JH, Shin JU, et al. Facial redness in atopic dermatitis patients treated with dupilumab: a case series. Allergy Asthma Immunol Res. 2020;12(6):1063–1065. doi: 10.4168/aair.2020.12.6.1063.
    1. Price KN, Krase JM, Loh TY, Hsiao JL, Shi VY. Racial and ethnic disparities in global atopic dermatitis clinical trials. Br J Dermatol. 2020;183(2):378–380. doi: 10.1111/bjd.18938.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir